findmyKOL

Rup Tandan, MD

Enriched profile

Professor of Neurology and Vice Chair of Clinical Affairs, Department of Neurological Sciences · University of Vermont Medical Center

ORCIDNone on fileNPI↗
✓ Full profile
Region🇺🇸 Burlington, VT · Northeast · United StatesSpecialtyNeurologyFocusCIDP / Inflammatory Neuropathy+2
Active KOLfindmyKOL type: EliteLatest publication2021Online presenceverified 2026Payments2022–2025NIH funding1994–2010Why? →

Rup Tandan is Professor of Neurology and Vice Chair of Clinical Affairs, Department of Neurological Sciences at University of Vermont Medical Center. ClinicalTrials.gov lists 4 registered studies with this person as an investigator.

Data verified 11 Oct 2026

Overview

Updated 16 Oct 2026

Rup Tandan, M.D., FRCP, is Professor of Neurology and Vice Chair of Clinical Affairs, Department of Neurological Sciences at University of Vermont Medical Center / Larner College of Medicine, University of Vermont. The public record shows 134 publications with 7,581 citations (h-index 38), centered on CIDP / Inflammatory Neuropathy, Myasthenia Gravis, Polyradiculoneuropathy. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 6 companies, 1 NIH-funded awards (1994–2010).

  • Top research focus: CIDP / Inflammatory Neuropathy
  • 4 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 6 companies

Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Myasthenia Gravis2 trialsAsthenia2 trialsCIDP / Inflammatory Neuropathy1 trialPolyradiculoneuropathy1 trialMyositis1 trialDermatomyositis1 trialPolymyositis1 trial

Research focus

OpenAlex concept fingerprint
CIDP / Inflammatory NeuropathyMyasthenia GravisPolyradiculoneuropathy

Drugs & molecules

across trials, industry payments and publications
Relyvriogeneric · Phenylbutyrate / taurursodiolClinical trials—Industry payments13Publications—Vyvgartgeneric · Efgartigimod alfaClinical trials—Industry payments7Publications—Qalsodygeneric · TofersenClinical trials—Industry payments1Publications—Skyclarysgeneric · OmaveloxoloneClinical trials—Industry payments1Publications—Solirisgeneric · EculizumabClinical trials—Industry payments1Publications—Spinrazageneric · NusinersenClinical trials—Industry payments1Publications—Ultomirisgeneric · RavulizumabClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Amylyx Pharmaceuticals, Inc.Clinical trials—Industry payments13Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments8Argenx Us, Inc.Clinical trials—Industry payments7Apellis Pharmaceuticals, Inc.Clinical trials—Industry payments4Alexion Pharmaceuticals, Inc.Clinical trials—Industry payments2Biogen, Inc.Clinical trials—Industry payments2Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyClinical trials1Industry payments—National Center for Research Resources (NCRR)Clinical trials1Industry payments—Phoenix Neurological Associates, LTDClinical trials1Industry payments—University of VermontClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
38h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
4clinical trials

Investigator role on registered studies.

View trials ↓
6companies · 2022–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 1994–2010

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 16 Oct 2026

Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 16 Oct 2026

6 companies reported payments to CMS in program years 2022–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    100%
    Other nervous system drugs40%
    Radicava Ors100%
    Part D≥14 patients
    Benzothiazole31.6%
    Riluzole100%
    Part D≥14 patients

    + 3 more classes in this area

Where care is delivered (Part B)57.8% facility · 42.2% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 16 Oct 2026

1 NIH research award on record, funded 1994–2010 per NIH RePORTER. The latest:

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Online presence

Updated 16 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/rup-tandan-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 16 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Director

    National ALS Clinical & Research Center, University of Vermont

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vermontbiz.com ↗
  • Director

    Muscular Dystrophy Association clinic, University of Vermont

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vermontbiz.com ↗
  • Fellow

    American Academy of Neurology (FAAN)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cmtausa.org ↗

Secondary affiliations

appointments beyond the home institution
  • Director

    Neuromuscular Disorders Section and Neuromuscular Fellowship Program, UVM Medical Center

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vermontbiz.com ↗

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.